| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI133388 | A chemical proteomics survey of Plasmodium gametocyte development | 001 | 1 | NIH | 9/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = -$67,702 ) |
| | 2021 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | F32AI126703 | The role of vitamin D receptor signaling in T cells during Mycobacterium tuberculosis infection | 000 | 2 | NIH | 1/12/2021 | -$6,348 |
| | 2021 | 2015 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI100018 | Myeloid-derived Suppressor cells (MDSC) suppress infant immune responses | 002 | 4 | NIH | 10/3/2020 | $61,354 |
| | 2021 | 2015 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI100018 | Myeloid-derived Suppressor cells (MDSC) suppress infant immune responses | 001 | 4 | NIH | 10/3/2020 | -$61,354 |
| | 2021 | 2015 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI100018 | Myeloid-derived Suppressor cells (MDSC) suppress infant immune responses | 000 | 4 | NIH | 10/1/2020 | -$61,354 |
|
| Issue Date FY: 2020 ( Subtotal = -$14,039 ) |
| | 2020 | 2015 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | K08HD069201 | Assessing feeding practices, immune activation, and HIV risk in African infants | 000 | 5 | NIH | 3/25/2020 | -$173 |
| | 2020 | 2014 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | P01AI094419 | Optimizing HIV immunogen-BCR interactions for vaccine development | 000 | 4 | NIH | 10/1/2019 | -$3,903 |
| | 2020 | 2014 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI105769 | Ribosome Profiling in Plasmodium falciparum | 000 | 2 | NIH | 10/1/2019 | -$97 |
| | 2020 | 2014 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | P01AI094419 | Optimizing HIV immunogen-BCR interactions for vaccine development | 001 | 4 | NIH | 10/1/2019 | -$9,866 |
|
| Issue Date FY: 2019 ( Subtotal = -$15,427,608 ) (Continued on the next page) |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI135680 | Exosome-based biomarkers of persistent vivax malaria liver infection | 002 | 1 | NIH | 1/18/2019 | -$2,493 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI135680 | Exosome-based biomarkers of persistent vivax malaria liver infection | 005 | 1 | NIH | 4/30/2019 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI133369 | A systems genetics approach to determine factors regulating Plasmodium falciparum sporozoite infectivity | 003 | 2 | NIH | 4/30/2019 | -$77,523 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI137815 | Structural Analysis and inhibitor optimization of Cryptosporidium n-myristoyltransferase for drug discovery | 000 | 1 | NIH | 11/21/2018 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI137815 | Structural Analysis and inhibitor optimization of Cryptosporidium n-myristoyltransferase for drug discovery | 002 | 1 | NIH | 4/30/2019 | -$123,152 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R03AI131223 | Multigene knockdown in Mycobacterium tuberculosis by repurposing the endogenous type III CRISPR system | 004 | 2 | NIH | 4/30/2019 | -$21,371 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R03AI131223 | Multigene knockdown in Mycobacterium tuberculosis by repurposing the endogenous type III CRISPR system | 002 | 2 | NIH | 1/17/2019 | $20,548 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI114766 | Adhesive Interactions in Severe Malaria | 000 | 4 | NIH | 1/10/2019 | -$432,357 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01GM101183 | Perturbations of host cell signaling by a complex hepatotropic pathogen | 003 | 6 | NIH | 5/13/2019 | -$6,822 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01GM101183 | Perturbations of host cell signaling by a complex hepatotropic pathogen | 000 | 6 | NIH | 2/14/2019 | -$218,724 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI032972 | LPS Signaling in Macrophages: The Roll of Toll | 005 | 28 | NIH | 4/30/2019 | -$58,582 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI032972 | LPS Signaling in Macrophages: The Roll of Toll | 002 | 28 | NIH | 1/10/2019 | $48,153 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI032972 | LPS Signaling in Macrophages: The Roll of Toll | 000 | 28 | NIH | 12/7/2018 | -$857,558 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI133388 | A chemical proteomics survey of Plasmodium gametocyte development | 000 | 1 | NIH | 12/21/2018 | -$281,132 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | U19AI128914 | Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization | 000 | 2 | NIH | 1/16/2019 | -$791,504 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | U19AI128914 | Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization | 000 | 2 | NIH | 1/16/2019 | -$1,977,025 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R03AI137599 | Phosphotyrosine Recognition in Bacteria | 003 | 1 | NIH | 4/30/2019 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R03AI137599 | Phosphotyrosine Recognition in Bacteria | 000 | 1 | NIH | 12/21/2018 | -$52,077 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | U19AI135976 | Omics for TB: Response to Infection and Treatment | 002 | 1 | NIH | 2/19/2019 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | U19AI135976 | Omics for TB: Response to Infection and Treatment | 000 | 1 | NIH | 1/14/2019 | -$2,050,866 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI117023 | The role of Ser/Thr/Tyr phosphosignaling in the M. tuberculosis latency switch | 005 | 3 | NIH | 5/1/2019 | -$43,330 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI117023 | The role of Ser/Thr/Tyr phosphosignaling in the M. tuberculosis latency switch | 002 | 3 | NIH | 1/10/2019 | $14,691 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01HL130488 | 3D human-based microvessel bed for the study of Plasmodium falciparum interacting with vessel wall | 003 | 4 | NIH | 6/24/2019 | -$464,949 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01HL130488 | 3D human-based microvessel bed for the study of Plasmodium falciparum interacting with vessel wall | 000 | 4 | NIH | 5/31/2019 | -$99,884 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI117234 | Infection-blocking antibody targets for malaria | 003 | 3 | NIH | 4/30/2019 | -$104,161 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI117234 | Infection-blocking antibody targets for malaria | 001 | 3 | NIH | 12/24/2018 | -$426,052 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134956 | Molecular Determinants of Sporozoite / Host Cell Interactions | 005 | 1 | NIH | 7/23/2019 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134956 | Molecular Determinants of Sporozoite / Host Cell Interactions | 002 | 1 | NIH | 12/19/2018 | -$421,629 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134956 | Molecular Determinants of Sporozoite / Host Cell Interactions | 001 | 1 | NIH | 12/11/2018 | -$503,500 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134956 | Molecular Determinants of Sporozoite / Host Cell Interactions | 001 | 1 | NIH | 12/11/2018 | $503,500 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134956 | Molecular Determinants of Sporozoite / Host Cell Interactions | 000 | 1 | NIH | 10/30/2018 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134956 | Molecular Determinants of Sporozoite / Host Cell Interactions | 000 | 1 | NIH | 10/30/2018 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI135680 | Exosome-based biomarkers of persistent vivax malaria liver infection | 000 | 1 | NIH | 12/14/2018 | -$182,377 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI130685 | Protein kinase AEK1 as a T. brucei drug target and its potential in other trypanosomatids | 005 | 1 | NIH | 7/23/2019 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI137571 | Serine hydrolase regulators of Mycobacterium tuberculosis non-replicating states | 000 | 1 | NIH | 12/19/2018 | -$241,486 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI137571 | Serine hydrolase regulators of Mycobacterium tuberculosis non-replicating states | 003 | 1 | NIH | 4/30/2019 | $0 |
| | 2019 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI133369 | A systems genetics approach to determine factors regulating Plasmodium falciparum sporozoite infectivity | 000 | 2 | NIH | 1/10/2019 | -$167,477 |
|
